These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 13980787)

  • 1. [Plasmocytoma and Endoxan therapy].
    TEUSCHER G
    Hippokrates; 1962 Oct; 33():818-9. PubMed ID: 13980787
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results of the treatment of plasmocytoma with endooxan].
    ZOETL E
    Munch Med Wochenschr; 1962 Dec; 104():2414-5. PubMed ID: 14003866
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
    Gojo I; Guo C; Sarkodee-Adoo C; Meisenberg B; Fassas A; Rapoport AP; Cottler-Fox M; Heyman M; Takebe N; Tricot G
    Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of plasmocytoma].
    WIGAND H
    Arztl Wochensch; 1953 Nov; 8(46):1097-1100. PubMed ID: 13104242
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical aspects of radiophosphorus therapy of seven cases of plasmocytoma].
    ALCOZER G; FERRINI O; PENDE G
    Arch Maragliano Patol Clin; 1957 Oct; 13(5):1225-46. PubMed ID: 13488578
    [No Abstract]   [Full Text] [Related]  

  • 9. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.
    Kraut EH; Young D; Farag S; James AG; Solove RJ
    Leuk Res; 2005 Oct; 29(10):1233-4. PubMed ID: 16111541
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
    Hovenga S; Daenen SM; de Wolf JT; van Imhoff GW; Kluin-Nelemans HC; Sluiter WJ; Vellenga E
    Ann Hematol; 2005 May; 84(5):311-6. PubMed ID: 15605244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The disorder of carbohydrate metabolism as a result of diamidine therapy of plasmocytoma].
    GERHARTZ H; KOCH H
    Dtsch Arch Klin Med; 1954; 201(3):249-56. PubMed ID: 13200304
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of endoxan on oxidative processes in model systems in vitro.
    Mileva M; Traikov L; Deliyska B
    Med Pregl; 2007; 60 Suppl 2():121-3. PubMed ID: 18928176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
    Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
    Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelomatous pleural effusion.
    Gogia A; Agarwal PK; Jain S; Jain KP
    J Assoc Physicians India; 2005 Aug; 53():734-6. PubMed ID: 16398088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
    Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [On the therapy of plasmacytoma with the nitrogen mustard cyclophosphamide ester endoxan].
    SCHUMACHER K; LANGE J; FRITZ KW
    Munch Med Wochenschr; 1962 Nov; 104():2110-7. PubMed ID: 13987289
    [No Abstract]   [Full Text] [Related]  

  • 19. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
    Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
    Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.